CRLF2重排急性淋巴细胞白血病中Janus激酶的降解
CRLF2重排(CRLF2r)急性淋巴细胞白血病(ALL)占费城染色体样(Ph样)ALL半数以上,儿童和成人预后差。研究基于I型JAK抑制剂与JAK2激酶域共晶结构,设计cereblon(CRBN)导向的JAK PROTACs,在多株白血病/淋巴瘤细胞系及激酶驱动ALL异种移植模型中评估降解与杀伤活性。多种PROTAC可降解JAK并强效杀伤CRLF2r细胞系,其中双JAK/GSPT1降解PROTAC活性最强,而保留GSPT1的JAK2降解PROTAC在多数对I型JAK抑制剂无应答的激酶驱动异种移植中显示疗效。
要点
- JAK PROTACs可降解JAK并强效杀伤CRLF2r ALL细胞系。
- 双JAK/GSPT1降解PROTAC活性最强,如化合物7(SJ988497)。
- 保留GSPT1的JAK2降解PROTAC在多数JAK抑制剂耐药异种移植中有效,如化合物8(SJ1008030)。
核心结论
- JAK导向的蛋白降解是JAK-STAT驱动ALL的潜在治疗策略。
- JAK与GSPT1降解活性在该背景下存在相互作用。
研究设计与样本
- 基于ruxolitinib和baricitinib与JAK2酪氨酸激酶域共晶结构,理性设计CRBN导向的JAK PROTACs。
- PROTACs由JAK抑制剂衍生物、连接子和CRBN特异性分子胶组成。
- 在白血病/淋巴瘤细胞系面板及激酶驱动ALL异种移植模型中评估靶点降解与活性。
主要发现
- 多种PROTAC可降解JAK并强效杀伤CRLF2r细胞系。
- 最活跃的PROTAC还降解已知CRBN新底物GSPT1,并在体内抑制CRLF2r ALL增殖,如化合物7(SJ988497)。
- 双JAK/GSPT1降解PROTAC活性最强。
- 在扩展异种移植面板中鉴定出强效JAK2降解、保留GSPT1的PROTAC,在多数对I型JAK抑制剂无应答的激酶驱动异种移植中显示疗效,如化合物8(SJ1008030)。
临床怎么用
- JAK PROTACs可能用于CRLF2r/Ph样ALL,尤其对I型JAK抑制剂应答不佳者。
- 双JAK/GSPT1降解与保留GSPT1的JAK2降解策略需根据疗效与毒性进一步权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) accounts for more than half of Philadelphia chromosome-like (Ph-like) ALL and is associated with a poor outcome in children and adults. Overexpression of CRLF2 results in activation of Janus kinase (JAK)-STAT and parallel signaling pathways in experimental models, but existing small molecule inhibitors of JAKs show variable and limited efficacy. Here, we evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against JAKs. Solving the structure of type I JAK inhibitors ruxolitinib and baricitinib bound to the JAK2 tyrosine kinase domain enabled the rational design and optimization of a series of cereblon (CRBN)-directed JAK PROTACs utilizing derivatives of JAK inhibitors, linkers, and CRBN-specific molecular glues. The resulting JAK PROTACs were evaluated for target degradation, and activity was tested in a panel of leukemia/lymphoma cell lines and xenograft models of kinase-driven ALL. Multiple PROTACs were developed that degraded JAKs and potently killed CRLF2r cell lines, the most active of which also degraded the known CRBN neosubstrate GSPT1 and suppressed proliferation of CRLF2r ALL in vivo, e.g. compound 7 (SJ988497). Although dual JAK/GSPT1-degrading PROTACs were the most potent, the development and evaluation of multiple PROTACs in an extended panel of xenografts identified a potent JAK2-degrading, GSPT1-sparing PROTAC that demonstrated efficacy in the majority of kinase-driven xenografts that were otherwise unresponsive to type I JAK inhibitors, e.g. compound 8 (SJ1008030). Together, these data show the potential of JAK-directed protein degradation as a therapeutic approach in JAK-STAT-driven ALL and highlight the interplay of JAK and GSPT1 degradation activity in this context.
引用
- Chang Y, Min J, Jarusiewicz JA, et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021. PMID: 34110416. doi:10.1182/blood.2020006846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。